Balyasny Asset Management
KNSA icon

Balyasny Asset Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Balyasny Asset Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.1M Buy
+499,792
New +$22.1M 0.03% 611
2025
Q2 		– Sell
-13,373
Closed -$297K – 3104
2025
Q1 		$297K Buy
13,373
+452
+3% +$9.3K ﹤0.01% 2452
2024
Q4 		$256K Buy
+12,921
New +$295K ﹤0.01% 2456
2024
Q2 		– Sell
-26,200
Closed -$517K – 2857
2024
Q1 		$517K Sell
26,200
-20,089
-43% -$392K ﹤0.01% 2039
2023
Q4 		$812K Buy
+46,289
New +$761K ﹤0.01% 1767
2023
Q1 		– Sell
-2,695
Closed -$40.4K – 2918
2022
Q4 		$40.4K Buy
+2,695
New +$39.2K ﹤0.01% 2376
2021
Q3 		– Sell
-400,296
Closed -$5.58M – 2191
2021
Q2 		$5.58M Buy
+400,296
New +$6.08M 0.03% 677

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Balyasny Asset Management's KNSA Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q1 2026: 499,792 shares worth $24.1M. The stake represents 0.03% of the portfolio and ranks #611 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in KNSA as recently as Q1 2025.

Balyasny Asset Management first reported a position in KNSA in Q2 2021 and has held it in 7 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Balyasny Asset Management held 499,792 shares of Kiniksa Pharmaceuticals worth $24.1M as of Q1 2026.
  • Kiniksa Pharmaceuticals was a new Balyasny Asset Management position in Q1 2026.
  • Kiniksa Pharmaceuticals made up 0.03% of Balyasny Asset Management's portfolio in Q1 2026, its #611 holding.
  • Balyasny Asset Management first reported a position in Kiniksa Pharmaceuticals in Q2 2021 and has held it in 7 quarters since.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.